Difference between models that consider either the deletion of critical genes for developing NKT cells, deletion of CD1d genes, or administration of blocking antibodies should weigh whether such approaches effectively allow evaluating the participation of NKT cells on allergic asthma, taking into consideration the different subtypes of NKT cells that exist. This evidence concerns the gene CD1D and allergic asthma.